Oasmia Pharmaceutical has announced the appointment of Reinhard Koenig as Chief Scientific Officer with immediate effect.
Koenig is an experienced executive with over 25 years’ experience at life-science companies, many of them operating internationally, states the company in a press release. He has a deep understanding of successful product development and commercialization of medicines in the fields of cancer, immunology, neurology, cardiology, critical care, dermatology, and a track record of obtaining approvals worldwide.
An exciting time
Prior to working at Oasmia, Koenig held various positions ranging from subject matter specialist to C-level executive and director. Previous companies include Boehringer Mannheim, Genentech, Questcor and Piramal Critical Care, amongst others.
“Oasmia is at an exciting time in its ongoing transformation. As Oasmia’s new CSO I look forward to continuing my work with Francois and the new leadership team. In addition to guiding the progress of Oasmia’s current development candidates, I am also looking forward to evaluating in-licensing and M&A opportunities to help build the product portfolio,” says Koenig.